Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. RESULTS: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. CONCLUSIONS: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the earlier ENHANCE trial could not confirm that an addition of ezetimibe to statins significantly reduces intima-media thickness in patients with familial hypercholesterolemia, the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
In the citing paper
“the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationBots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationBuchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Howard, G., Sharrett, A. R., Heiss, G., Evans, G. W., Chambless, L. E., Riley, W. A., & Burke, G. L. (1993) · Stroke · doi:10.1161/01.str.24.9.1297 · Cited by 724
Ballantyne, C. M., Houri, J., Notarbartolo, A., Melani, L., Lipka, L. J., Suresh, R., Sun, S., LeBeaut, A. P., Sager, P. T., & Veltri, E. P. (2003) · Circulation · doi:10.1161/01.cir.0000068312.21969.c8 · Cited by 687
Self-citationEffect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Self-citationMonogenic hypercholesterolemia: new insights in pathogenesis and treatment
Rader, D. J., Cohen, J., & Hobbs, H. H. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18925 · Cited by 560
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
Davidson, M. H., McGarry, T., Bettis, R., Melani, L., Lipka, L. J., LeBeaut, A. P., Suresh, R., Sun, S., & Veltri, E. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02610-4 · Cited by 558
Self-citationTaylor, A. J., Kent, S. M., Flaherty, P. J., Coyle, L. C., Markwood, T. T., & Vernalis, M. N. (2002) · Circulation · doi:10.1161/01.cir.0000034508.55617.65 · Cited by 558
Measurement of Arterial Wall Thickness as a Surrogate Marker for Atherosclerosis
de Groot, E., Hovingh, G. K., Wiegman, A., Duriez, P., Smit, A. J., Fruchart, J.-C., & Kastelein, J. J. P. (2004) · Circulation · doi:10.1161/01.cir.0000131516.65699.ba · Cited by 556
Self-citationInflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Schönbeck, U., & Libby, P. (2004) · Circulation · doi:10.1161/01.cir.0000129505.34151.23 · Cited by 498
Landmesser, U., Bahlmann, F., Mueller, M., Spiekermann, S., Kirchhoff, N., Schulz, S., Manes, C., Fischer, D., de Groot, K., Fliser, D., et al. (2005) · Circulation · doi:10.1161/01.cir.0000164260.82417.3f · Cited by 425
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 407
Hedblad, B., Wikstrand, J., Janzon, L., Wedel, H., & Berglund, G. (2001) · Circulation · doi:10.1161/01.cir.103.13.1721 · Cited by 325
Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia
Wiegman, A., de Groot, E., Hutten, B. A., Rodenburg, J., Gort, J., Bakker, H. D., Sijbrands, E. J., & Kastelein, J. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15467-6 · Cited by 324
Self-citationHodis, H. N., Mack, W. J., LaBree, L., Selzer, R. H., Liu, C.-R., Liu, C.-H., Alaupovic, P., Kwong-Fu, H., & Azen, S. P. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-6-199603150-00002 · Cited by 323
de Groot, E., Jukema, J. W., Montauban van Swijndregt, A. D., Zwinderman, A. H., Ackerstaff, R. G. A., van der Steen, A. F. W., Bom, N., Lie, K. I., & Bruschke, A. V. G. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00170-3 · Cited by 258
Self-citationMacMahon, S., Sharpe, N., Gamble, G., Hart, H., Scott, J., Simes, J., & White, H. (1998) · Circulation · doi:10.1161/01.cir.97.18.1784 · Cited by 254
Fichtlscherer, S., Schmidt‐Lucke, C., Bojunga, S., Rössig, L., Heeschen, C., Dimmeler, S., & Zeiher, A. M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi881 · Cited by 140
Deficiency of Niemann-Pick C1 Like 1 Prevents Atherosclerosis in ApoE−/−Mice
Davis, H. R., Hoos, L. M., Tetzloff, G. G., Maguire, M., Zhu, L.-J., Graziano, M. P., & Altmann, S. W. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000257627.40486.46 · Cited by 122
Buchwald, H., Varco, R. L., Boen, J. R., Williams, S. E., Hansen, B. J., Campos, C. T., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., et al. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.11.1253 · Cited by 116
Kastelein, J. J. P., Sager, P. T., de Groot, E., & Veltri, E. P. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.06.024 · Cited by 101
Self-citationCrouse, J. R., Grobbee, D. E., O’Leary, D. H., Bots, M. L., Evans, G. W., Palmer, M. K., Riley, W. A., & Raichlen, J. S. (2004) · Cardiovascular Drugs and Therapy · doi:10.1023/b:card.0000033645.55138.3d · Cited by 85
Self-citationvan Wissen, S., Smilde, T. J., Trip, M. D., Stalenhoef, A. F. H., & Kastelein, J. J. P. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.09.015 · Cited by 64
Self-citationBulut, D., Hanefeld, C., Bulut-Streich, N., Graf, C., Mügge, A., & Spiecker, M. (2005) · Cardiology · doi:10.1159/000088105 · Cited by 41
Espeland, M. A., Craven, T. E., Miller, M. E., & D’Agostino, R. (1999) · Annals of Epidemiology · doi:10.1016/s1047-2797(98)00069-6 · Cited by 22
Cited by
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
“emia, adding ezetimibe to simvastatin did not affect the progression of carotid IMT more than simvastatin alone.(179) In another”
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
“percholesterolemia despite a 17% lower level of LDL-C (622).”
BackgroundValidity and reliability of measurement instruments used in research
Kimberlin, C. L., & Winterstein, A. G. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070364 · Cited by 1,717
“Most recently, the Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Subjects with Heterozygous Familial Hypercholesterolemia (ENHANCE) trial found negative results for effects on intima–media thickness, even though the combination of ezetimibe and simvast…”
Result
Metadata
- Authors
- Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-04-03
- Volume
- 358
- Issue
- 14
- Pages
- 1431-1443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120289695
- Semantic Scholar
- 0da4a48a4d402878a4b01330a3e43a185140f586
- Cited by
- 1,241
- References
- 34
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 27 · 2019: 35 · 2018: 30 · 2017: 38 · 2016: 50 · 2015: 77 · 2014: 91 · 2013: 85 · 2012: 111
- FWCI
- 210.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, ezetimibe, familial hypercholesterolemia, LDL cholesterol lowering, atherosclerosis progression, carotid intima-media thickness, femoral artery, cholesterol absorption inhibition, triglycerides, C-reactive protein, statin combination therapy, lipid-lowering therapy, atherosclerotic plaque regression
- MeSH terms
- Ezetimibe, Adult, Anticholesteremic Agents, Azetidines, Carotid Arteries, Cholesterol, Double-Blind Method, Drug Therapy, Combination, Female, Femoral Artery, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Ultrasonography, Treatment Outcome, Tunica Intima, Tunica Media, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.